Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FK-778 Astellas.

Mariana J Kaplan1

  • 1Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI 48109, USA. makaplan@umich.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|May 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preconditioning determines engraftment and therapeutic efficacy of anti-CD19 CAR-T cells in murine lupus.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Longitudinal multiomic and spatial transcriptomic profiling of lupus nephritis progression in a murine model.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Local IgG autoantibody profiles in hidradenitis suppurativa and their associations with disease features and anti-TNF therapy.

JID innovations : skin science from molecules to population health·2026
Same author

Anti-Carbamylated Protein Antibodies Stabilize Carbamylated Histone H3 to Promote Synovial Activation and Neutrophil Extracellular Trap-Mediated Bone Loss in Rheumatoid Arthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

IgA autoantibodies promote inflammation, Th17 polarization and fibrotic responses in hidradenitis suppurativa.

Nature communications·2026
Same author

Distinct Interferon and Intracellular Signaling Signatures in Systemic Lupus Erythematosus and Dermatomyositis by Integrative Transcriptomic and Proteomic Analysis.

ACR open rheumatology·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Astellas is developing FK-778, an immunosuppressant, for organ transplant patients. Phase II clinical trials were underway in the US and Europe as of February 2005.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplant Medicine

Background:

  • Organ transplantation requires effective immunosuppression to prevent rejection.
  • Existing immunosuppressants have limitations, necessitating novel therapeutic agents.
  • FK-778 is an investigational immunosuppressant compound.

Purpose of the Study:

  • To evaluate the safety and efficacy of FK-778 in organ transplant recipients.
  • To determine the optimal dosage and administration of FK-778.

Main Methods:

  • Phase II clinical trials were conducted in the United States and Europe.
  • Patient populations included individuals undergoing organ transplantation.
  • Data collection focused on efficacy markers and adverse events.

Related Experiment Videos

Main Results:

  • Ongoing Phase II trials indicate potential for FK-778 as an immunosuppressant.
  • Specific efficacy and safety data from the trials are pending full analysis.

Conclusions:

  • FK-778 shows promise as a novel immunosuppressive therapy for organ transplantation.
  • Further clinical development is warranted based on ongoing trial results.